Chi­na’s biotech mar­ket is stag­ing a come­back that US biotech can on­ly wish for

Chi­na’s bio­phar­ma­ceu­ti­cal sec­tor is show­ing signs of re­vival from its post-pan­dem­ic slump, even as its US coun­ter­part re­mains in a rut.

Buoyed by li­cens­ing deals …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER